Actively Recruiting
Phase 12 Open-Label Study of Intravenous ML-016 in Adults With Advanced Solid Tumors Involving Lung andor Liver
Led by BrYet US, Inc. · Updated on 2026-10-05
108
Participants Needed
3
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ML-016, a drug being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor effects in adults with advanced or metastatic solid tumors involving the lung andor liver. This open-label, multi-center phase 12 trial includes participants whose cancer is refractory to standard treatments or for whom no curative options exist or are acceptable. The study aims to identify appropriate dosing and assess the drugs impact on tumor control. ML-016 will be given as an intravenous infusion on Day 1 of each 21-day treatment cycle. The study includes a dose-escalation phase to determine safe dosing levels, followed by a dose-expansion phase testing two dose levels in disease-specific groups. Treatment will continue until disease progression or other discontinuation criteria are met. Participants will undergo regular evaluations including blood tests for safety, vital signs, heart function assessments with electrocardiograms and echocardiograms, and imaging studies to measure tumor response. Researchers will monitor adverse events, drug levels, and various survival outcomes over time. The study duration varies based on treatment continuation and follow-up, with primary safety assessments focused on the first 21 days of treatment cycles.
CONDITIONS
Brief Title
ML-016 in Advanced Cancer With Lung and/or Liver Involvement
Research Team
A
Amanda Jubb, Clinical Project Manager, Southern Star Research
M
Matt Wagener, VP Clinical Development Operations, BrYet
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here